Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SAIL66 |
Trade Name | |
Synonyms | SAIL 66|SAIL-66 |
Drug Descriptions |
SAIL66 is a T-cell engager that targets CLDN6 on cancer cells and also binds to CD3 and TNFRSF9 (CD137), potentially inducing T-cell activation, cytokine release, and antitumor immune activity (J Immunother Cancer 2023;11(Suppl 1):1172). |
DrugClasses | CLDN6 Antibody 8 TNFRSF9 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C200201 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
SAIL66 | SAIL66 | 0 | 0 |
SAIL66 + Tocilizumab | SAIL66 Tocilizumab | 0 | 1 |